Entera Bio Ltd.
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
ENTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- IL0011429839
- LEI:
- Country:
- United States of America
- Address:
- KIRYAT HADASSAH, MINRAV BUILDING, 9112002 JERUSALEM
- Website:
- https://enterabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of orally delivered large molecule and peptide therapeutics. The company's proprietary N-Tab™ technology platform enables the oral administration of drugs that are typically injectable by stabilizing the active ingredients in the gastrointestinal tract and enhancing absorption. Entera's primary focus is on therapies for significant unmet medical needs. Its clinical pipeline is led by EB613, an oral parathyroid hormone (PTH) tablet for postmenopausal women with osteoporosis, and EB612 for patients with hypoparathyroidism. The company is also developing oral treatments for obesity and rare malabsorption conditions like short bowel syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Entera Bio Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Entera Bio Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Entera Bio Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
